Stifel Nicolaus Raises Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $207.00

Ascendis Pharma A/S (NASDAQ:ASND) had its target price increased by investment analysts at Stifel Nicolaus from $200.00 to $207.00 in a report released on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Stifel Nicolaus’ price target would suggest a potential upside of 66.56% from the company’s previous close.

Other analysts also recently issued reports about the company. TD Cowen lifted their price target on Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, November 4th. Citigroup increased their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. JPMorgan Chase & Co. decreased their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. Finally, Evercore ISI raised their price objective on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research note on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $193.08.

Ascendis Pharma A/S Stock Down 1.4 %

Shares of ASND opened at $124.28 on Friday. The firm’s 50 day moving average price is $132.15 and its 200 day moving average price is $132.80. Ascendis Pharma A/S has a fifty-two week low of $90.13 and a fifty-two week high of $161.00. The company has a market cap of $7.54 billion, a P/E ratio of -13.35 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. Research analysts forecast that Ascendis Pharma A/S will post -7.35 earnings per share for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Signaturefd LLC raised its stake in shares of Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares in the last quarter. Bessemer Group Inc. boosted its position in shares of Ascendis Pharma A/S by 61.0% during the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 332 shares in the last quarter. Searle & CO. bought a new stake in Ascendis Pharma A/S in the second quarter valued at about $205,000. Rhumbline Advisers lifted its position in shares of Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after buying an additional 143 shares during the period. Finally, Pursue Wealth Partners LLC acquired a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth about $217,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.